Filter
Sort by
View
58 cases found.

Turing Pharmaceuticals: Fair Profit or Price Gouging in the Drug Industry?

By  N. Craig Smith,  Erin McCormick
Add to cart popular
This case examines how a drug price increase by one small company, Turing Pharmaceuticals, became the focal point of a controversy that engulfed the entire drug industry. Turing’s decision to raise the price of its anti-infection drug Daraprim, from $13.50 to $750 per dose, is emblematic of the debate about the responsibilities of pharmaceutical companies and business more generally.

    Published 29 May 2017

    Reference 6253

    Topic Responsibility

    Region North America

    Industry Pharmaceuticals

    View case

    Turing Pharmaceuticals: Fair Profit or Price Gouging in the Drug Industry?

    Add to cart popular
    This case examines how a drug price increase by one small company, Turing Pharmaceuticals, became the focal point of a controversy that engulfed the entire drug industry. Turing’s decision to raise the price of its anti-infection drug Daraprim, from $13.50 to $750 per dose, is emblematic of the debate about the responsibilities of pharmaceutical companies and business more generally.
      View case

      Arogya Parivar: Novartis' BOP Strategy for Healthcare in Rural India

      By  Amitava Chattopadhyay,  Anuj Pasrija,  Olivier Jarry,  Jean Wee
      Add to cart popular extra
      With the publication of CK Prahalad’s “The Fortune at the Bottom of the Pyramid” (2005), the poor were suddenly seen as a potential market in the eyes of multinational corporations (MNCs). Although poor, the BOP is a large and growing market.

        Published 27 Oct 2014

        Reference 6088

        Topic Strategy

        Region Asia

        Industry Pharmaceuticals

        View case

        Arogya Parivar: Novartis' BOP Strategy for Healthcare in Rural India

        Add to cart popular extra
        With the publication of CK Prahalad’s “The Fortune at the Bottom of the Pyramid” (2005), the poor were suddenly seen as a potential market in the eyes of multinational corporations (MNCs). Although poor, the BOP is a large and growing market.
          View case

          Growth Strategies in the Pharmaceutical Industry (A)

          By  Shantanu Bhattacharya,  Sameer Hasija,  Sjiva De Meester
          Add to cart popular
          This case illustrates different growth strategies in the pharmaceutical industry. R&D management is a critical component of growth strategies, and the case demonstrates the importance of using a holistic framework for R&D when expanding the firm's business footprint.

            Published 21 Aug 2015

            Reference 6074

            Topic Operations

            Industry Pharmaceuticals

            View case

            Growth Strategies in the Pharmaceutical Industry (A)

            Add to cart popular
            This case illustrates different growth strategies in the pharmaceutical industry. R&D management is a critical component of growth strategies, and the case demonstrates the importance of using a holistic framework for R&D when expanding the firm's business footprint.
              View case

              Zoetis, Pfizer's Animal Health Spin-Off (B)

              By  Shantanu Bhattacharya,  Sameer Hasija,  Sjiva De Meester
              Add to cart
              This case illustrates different growth strategies in the pharmaceutical industry. R&D management is a critical component of growth strategies, and the case demonstrates the importance of using a holistic framework for R&D when expanding the firm's business footprint.

                Published 21 Aug 2015

                Reference 6074

                Topic Operations

                Industry Pharmaceuticals

                View case

                Zoetis, Pfizer's Animal Health Spin-Off (B)

                Add to cart
                This case illustrates different growth strategies in the pharmaceutical industry. R&D management is a critical component of growth strategies, and the case demonstrates the importance of using a holistic framework for R&D when expanding the firm's business footprint.
                  View case

                  Pulmocit: Negotiating Pharmaceutical Products with the Government (A) - Mr Simone Moretti (AhaPharma) - Confidential Instructions

                  By  Horacio Falcao,  Rodrigo Gouveia
                  Add to cart
                  This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.

                    Published 27 Jan 2014

                    Reference 6033

                    Topic Economics & Finance

                    Region Global

                    Industry Pharmaceuticals

                    View case

                    Pulmocit: Negotiating Pharmaceutical Products with the Government (A) - Mr Simone Moretti (AhaPharma) - Confidential Instructions

                    Add to cart
                    This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
                      View case

                      Pulmocit: Negotiating Pharmaceutical Products with the Government (B) - Dr Rozentale (Alpenian Government) - Confidential Instructions

                      By  Horacio Falcao,  Rodrigo Gouveia
                      Add to cart
                      This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.

                        Published 27 Jan 2014

                        Reference 6033

                        Topic Economics & Finance

                        Region Global

                        Industry Pharmaceuticals

                        View case

                        Pulmocit: Negotiating Pharmaceutical Products with the Government (B) - Dr Rozentale (Alpenian Government) - Confidential Instructions

                        Add to cart
                        This is a two-party negotiation between a pharmaceutical company and a government agency to decide if a new medication will be put on the reimbursement list. The pharmaceutical company has a valuable new product, the government has semi-monopolistic power over whether (or not) drugs are listed.
                          View case

                          Octapharma (A): Crisis and Leadership

                          By  Charles Galunic,  Philippe Ombregt
                          Add to cart
                          Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.

                            Published 27 Jan 2014

                            Reference 6031

                            Topic Leadership & Organisations

                            Region Europe

                            Industry Pharmaceuticals

                            View case

                            Octapharma (A): Crisis and Leadership

                            Add to cart
                            Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
                              View case

                              Octapharma (B): Crisis and Leadership

                              By  Charles Galunic,  Philippe Ombregt
                              Add to cart
                              Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.

                                Published 27 Jan 2014

                                Reference 6031

                                Topic Leadership & Organisations

                                Region Europe

                                Industry Pharmaceuticals

                                View case

                                Octapharma (B): Crisis and Leadership

                                Add to cart
                                Companies regularly face difficulties, but sometimes they have to face a "life threatening" crisis. Such events challenge leadership, not least because of their complexity - technological puzzles, loyalty and political maneuvering, branding and communication issues, to name a few.
                                  View case

                                  GlaxoSmithKline: U.S. Sales Practices

                                  By  N. Craig Smith,  Robert Crawford
                                  Add to cart
                                  In 2012, GlaxoSmithKline negotiated the largest health-fraud settlement to date with the U.S. Government over allegations of off-label marketing, bribing doctors, and failure to report drug safety problems. As well as the $3 billion settlement, GSK signed a five-year Corporate Integrity Agreement, which included corrective measures in sales and marketing practices.

                                    Published 29 Jun 2015

                                    Reference 6024

                                    Topic Responsibility

                                    Region Global

                                    Industry Pharmaceuticals

                                    View case

                                    GlaxoSmithKline: U.S. Sales Practices

                                    Add to cart
                                    In 2012, GlaxoSmithKline negotiated the largest health-fraud settlement to date with the U.S. Government over allegations of off-label marketing, bribing doctors, and failure to report drug safety problems. As well as the $3 billion settlement, GSK signed a five-year Corporate Integrity Agreement, which included corrective measures in sales and marketing practices.
                                      View case

                                      Oxipouco – An Endangered Species Resource Negotiation (A): SuperPharma - Confidential Instructions

                                      By  Horacio Falcao
                                      Add to cart award
                                      This two-party negotiation is an ideal introductory negotiation role-play to raise issues of assumptions, win-win/win-lose, competition/collaboration, interests/positions, single-/multi-issue, positions/options. Two companies, SuperPharma and PharmaCaring, both want to buy 10,000 rare Oxipouco fruits, which contain different compounds.

                                        Published 27 May 2013

                                        Reference 5977

                                        Topic Leadership & Organisations

                                        Region South America

                                        Industry Pharmaceuticals

                                        View case

                                        Oxipouco – An Endangered Species Resource Negotiation (A): SuperPharma - Confidential Instructions

                                        Add to cart award
                                        This two-party negotiation is an ideal introductory negotiation role-play to raise issues of assumptions, win-win/win-lose, competition/collaboration, interests/positions, single-/multi-issue, positions/options. Two companies, SuperPharma and PharmaCaring, both want to buy 10,000 rare Oxipouco fruits, which contain different compounds.
                                          View case

                                          Oxipouco – An Endangered Species Resource Negotiation (B): PharmaCaring - Confidential Instructions

                                          By  Horacio Falcao
                                          Add to cart award
                                          This two-party negotiation is an ideal introductory negotiation role-play to raise issues of assumptions, win-win/win-lose, competition/collaboration, interests/positions, single-/multi-issue, positions/options. Two companies, SuperPharma and PharmaCaring, both want to buy 10,000 rare Oxipouco fruits, which contain different compounds.

                                            Published 27 May 2013

                                            Reference 5977

                                            Topic Leadership & Organisations

                                            Region South America

                                            Industry Pharmaceuticals

                                            View case

                                            Oxipouco – An Endangered Species Resource Negotiation (B): PharmaCaring - Confidential Instructions

                                            Add to cart award
                                            This two-party negotiation is an ideal introductory negotiation role-play to raise issues of assumptions, win-win/win-lose, competition/collaboration, interests/positions, single-/multi-issue, positions/options. Two companies, SuperPharma and PharmaCaring, both want to buy 10,000 rare Oxipouco fruits, which contain different compounds.
                                              View case

                                              Building the Virtual Lab: Global Licensing and Partnering at Merck

                                              By  Thomas Klueter,  L. Felipe Monteiro
                                              Add to cart
                                              The case presents a situation in which Merck’s World Wide Licensing (WWL) division needs to make important organizational decisions to increase the speed, the breadth and the efficiency of its global licensing and partnering activities.

                                                Published 30 Jul 2014

                                                Reference 5962

                                                Topic Strategy

                                                Region Global

                                                Industry Pharmaceuticals

                                                View case

                                                Building the Virtual Lab: Global Licensing and Partnering at Merck

                                                Add to cart
                                                The case presents a situation in which Merck’s World Wide Licensing (WWL) division needs to make important organizational decisions to increase the speed, the breadth and the efficiency of its global licensing and partnering activities.
                                                  View case